scholarly journals Impact of Allergic Rhinitis on Quality of Life in Patients with Bronchial Asthma

2012 ◽  
Vol 6 (2) ◽  
pp. 186-194 ◽  
Author(s):  
Maha M. Elkholy ◽  
Mahmoud Hassan Khedr ◽  
Ashraf Halawa
Author(s):  
Soe AK ◽  
Aizat AF ◽  
Bellahcene MA ◽  
Atiqah N ◽  
Husna N

Allergic rhinitis (AR) and bronchial asthma (BA) are common inflammatory chronic respiratory diseases, and they are significant public health challenges on a global scale. The prevalence of these diseases are on the rise in all regions of the world, affecting all ages but more commonly among children and adolescences. Both AR and BA affect patients to a different extent with variable restrictions in the physical, emotional, and social aspects of the patient's life. They may be seen as two presentations of the same disease by sharing common epidemiologic, histologic, physiologic, and immunopathologic linkages. To determine the prevalence and impact of allergic rhinitis, asthma and allergic rhinitis with asthma on quality of life among secondary school students in Kinta District, Perak. A cross-sectional study was done among secondary school students from randomly selected three schools in Kinta District, Ipoh, Perak. A well-vetted and validated questionnaire was used to collect the data, and statistical analysis was done to determine the prevalence and impact of AR, BA, or both. A total of 250 secondary school students were involved in this study. Malays were the majority among the participants. The prevalence of AR alone, BA alone, and disease co-occurance were 27.2%, 9.2%, and 8%, respectively. Nearly 20% of the participants were troublesome but low scale in terms of quality of life followed by disturbed sleep, restricted participation in school, and daily activities. Only 6% of the participants experienced sleep disturbance due to asthma, but daily anti-asthmatic medication was essential in only 1.2%. This study showed that although a relatively high prevalence of allergic rhinitis and bronchial asthma. There was no significant low quality of life among sufferers.  


2017 ◽  
Vol 2 (2) ◽  
pp. 128-132
Author(s):  
A. E. Cherniakova ◽  
◽  
T. S. Ospanova ◽  
I. S. Karmazina

2018 ◽  
Vol 32 (3) ◽  
pp. 139-146 ◽  
Author(s):  
Jingang Ai ◽  
Zuozhong Xie ◽  
Xiang Qing ◽  
Wei Li ◽  
Honghui Liu ◽  
...  

Background The prevalence of both allergic rhinitis and bronchial asthma is high throughout the world; their mutual influence on each other has been documented in many studies. However, studies regarding surgical intervention are limited. Objective To evaluate the clinical significance of endoscopic vidian neurectomy on bronchial asthma outcomes in patients with coexisting refractory allergic rhinitis and asthma. Methods A total of 109 patients with moderate to severe persistent intractable allergic rhinitis and mild/moderate asthma were allocated to the bilateral endoscopic vidian neurectomy group (group 1) or conservative medication group (group 2) according to the patients’ self-selection. The Rhinoconjunctivitis Quality of Life Questionnaire, Visual Analog Scale, Asthma Quality of Life Questionnaire, Total Asthma Symptom Score, and medication scores were evaluated at six months, one year, and three years after undergoing the initial treatments. Multivariate analysis was performed to determine which triggers of asthma attacks were associated with improved asthma outcomes in patients. Results Ninety-five patients were followed up for at least three years. Postoperative scores of Rhinoconjunctivitis Quality of Life Questionnaire and Visual Analog Scale were significantly lower than preoperative scores during follow-up in group 1 and were significantly lower than those of group 2. Postoperative scores of Asthma Quality of Life Questionnaire at the three follow-up time points were higher than the preoperative scores in group 1. The Total Asthma Symptom Score was not significantly decreased in group 1. The medication scores for allergic rhinitis and asthma were gradually reduced after surgery. At the end of the follow-up, the improvement rates for allergic rhinitis and asthma were 90.6% and 45.3%, respectively. Asthma outcomes were significantly improved by controlling rhinitis symptoms in patients whose asthma attacks were induced by “rhinitis onset” or “weather change.” Conclusion Controlling allergic rhinitis symptoms by bilateral endoscopic vidian neurectomy can significantly improve asthma outcomes in patients whose asthma attacks are induced by rhinitis onset and/or cold air.


Author(s):  
Boris Stuck ◽  
Karl Hörmann ◽  
Joachim Maurer ◽  
Anna-Eva Hagner ◽  
Julia Johnson ◽  
...  

Author(s):  
Ludger Klimek ◽  
William E. Berger ◽  
Jean Bousquet ◽  
Paul K. Keith ◽  
Peter Smith ◽  
...  

Allergic rhinitis (AR) is prevalent, and many patients present with moderate-to-severe symptomatic disease. The majority of patients are not satisfied with their AR treatment, despite the use of concurrent medications. These gaps underscore the need for treatment with more effective options for moderate-to-severe AR. The authors’ objective was to review systematically the efficacy and safety of MP-AzeFlu for the treatment of AR. The primary outcomes studied were nasal, ocular, and total symptoms. Other outcomes included time to onset and of AR control, quality of life, and safety. Searches of PubMed and Cochrane databases were conducted on May 14, 2020, with no date restrictions, to identify publications reporting data on MP-AzeFlu. Clinical studies of any phase were included. Studies were excluded if they were not in English, were review articles, did not discuss the safety and efficacy of MP-AzeFlu for AR symptoms. Treatment of AR with MP-AzeFlu results in effective, sustained relief of nasal and ocular symptoms, and faster onset and time to control compared with intranasal azelastine or fluticasone propionate. Long-term use of MP-AzeFlu was safe, with benefits in children, adults, and adults aged ≥65 years. Other treatment options, including fluticasone propionate and azelastine alone or the combination of intranasal corticosteroids and oral antihistamine, do not provide the same level of efficacy as MP-AzeFlu in terms of rapid and sustained relief of the entire AR symptom complex. Furthermore, MP-AzeFlu significantly improves patient quality of life. MP-AzeFlu is a currently available combination that may satisfy all these patient needs and expectations.


2014 ◽  
Vol 6 (6) ◽  
pp. 541 ◽  
Author(s):  
Jeong Hee Kim ◽  
Young Mee Ahn ◽  
Hyung Jin Kim ◽  
Dae Hyun Lim ◽  
Byong Kwan Son ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document